BRPI0815360B8 - composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto - Google Patents

composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto

Info

Publication number
BRPI0815360B8
BRPI0815360B8 BRPI0815360A BRPI0815360A BRPI0815360B8 BR PI0815360 B8 BRPI0815360 B8 BR PI0815360B8 BR PI0815360 A BRPI0815360 A BR PI0815360A BR PI0815360 A BRPI0815360 A BR PI0815360A BR PI0815360 B8 BRPI0815360 B8 BR PI0815360B8
Authority
BR
Brazil
Prior art keywords
compound
preparation
pharmaceutical composition
composition containing
pyrimidinesulfamide
Prior art date
Application number
BRPI0815360A
Other languages
English (en)
Inventor
Treiber Alexander
Boss Christoph
Bolli Martin
Original Assignee
Actelion Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40140023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0815360(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0815360A2 publication Critical patent/BRPI0815360A2/pt
Publication of BRPI0815360A8 publication Critical patent/BRPI0815360A8/pt
Publication of BRPI0815360B1 publication Critical patent/BRPI0815360B1/pt
Publication of BRPI0815360B8 publication Critical patent/BRPI0815360B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

composto derivado de 4-pirimidinossulfamida, composição farma-cêutica que o contem, uso e processo para a preparação do com-posto a invenção diz respeito ao composto da fórmula estrutural (i) e os sais destes. o dito composto é usado como antagonista do receptor de endotelina. a invenção diz res-peito adicionalmente a um processo para preparar o dito composto.
BRPI0815360A 2007-08-17 2008-08-15 composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto BRPI0815360B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2007053292 2007-08-17
IB2008052571 2008-06-26
PCT/IB2008/053282 WO2009024906A1 (en) 2007-08-17 2008-08-15 4-pyrimidinesulfamide derivative

Publications (4)

Publication Number Publication Date
BRPI0815360A2 BRPI0815360A2 (pt) 2015-02-10
BRPI0815360A8 BRPI0815360A8 (pt) 2017-12-26
BRPI0815360B1 BRPI0815360B1 (pt) 2018-12-04
BRPI0815360B8 true BRPI0815360B8 (pt) 2021-05-25

Family

ID=40140023

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815360A BRPI0815360B8 (pt) 2007-08-17 2008-08-15 composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto

Country Status (26)

Country Link
US (1) US8324232B2 (pt)
EP (1) EP2190837B1 (pt)
JP (1) JP5323075B2 (pt)
KR (1) KR101528946B1 (pt)
CN (1) CN101772494B (pt)
AR (1) AR070018A1 (pt)
AU (1) AU2008290234B2 (pt)
BR (1) BRPI0815360B8 (pt)
CA (1) CA2695511C (pt)
CY (1) CY1113255T1 (pt)
DK (1) DK2190837T3 (pt)
ES (1) ES2394584T3 (pt)
HK (1) HK1144196A1 (pt)
HR (1) HRP20120878T1 (pt)
IL (1) IL203936A (pt)
MA (1) MA31702B1 (pt)
MX (1) MX2010001837A (pt)
MY (1) MY152281A (pt)
NZ (1) NZ583990A (pt)
PL (1) PL2190837T3 (pt)
PT (1) PT2190837E (pt)
RU (1) RU2485116C2 (pt)
SI (1) SI2190837T1 (pt)
TW (1) TWI411437B (pt)
WO (1) WO2009024906A1 (pt)
ZA (1) ZA201001872B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2907811A1 (en) * 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives
US10669264B2 (en) * 2015-11-30 2020-06-02 Laurus Labs Limited Process for the preparation of macitentan
WO2017191565A1 (en) * 2016-05-04 2017-11-09 Shilpa Medicare Limited Process for preparation of macitentan
KR20230074610A (ko) * 2017-02-27 2023-05-30 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물
CN111405899A (zh) * 2017-11-30 2020-07-10 爱杜西亚药品有限公司 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与sglt-2抑制剂的组合
CN108997223B (zh) * 2018-08-09 2020-06-30 浙江先锋科技股份有限公司 5-(4-溴苯基)-4，6-二氯嘧啶的制备方法
BR112021011999A2 (pt) 2018-12-21 2021-09-08 Actelion Pharmaceuticals Ltd Composição farmacêutica para o tratamento de hipertensão arterial pulmonar
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
AU2020378025A1 (en) * 2019-11-07 2022-06-23 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of Aprocitentan, preparation method therefor and use thereof
WO2021237004A1 (en) 2020-05-21 2021-11-25 Teva Pharmaceuticals International Gmbh Solid state forms of aprocitentan and process for preparation thereof
WO2023111797A1 (en) * 2021-12-17 2023-06-22 Janssen Biotech, Inc. Pyrimidine sulfamide derivatives and process for manufacturing them
WO2023227490A1 (en) 2022-05-22 2023-11-30 Idorsia Pharmaceuticals Ltd Aprocitentan for the treatment of hypertension
WO2023227721A1 (en) 2022-05-25 2023-11-30 Idorsia Pharmaceuticals Ltd Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801584A1 (de) 1978-01-14 1979-07-19 Bayer Ag Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
JPH04103525A (ja) 1990-08-22 1992-04-06 Sanwa Kagaku Kenkyusho Co Ltd 難水溶性薬物の持続性製剤化方法
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5523204A (en) 1993-12-10 1996-06-04 Becton Dickinson And Company Detection of nucleic acids in cells by strand displacement amplification
WO1996016963A1 (de) 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamide und deren verwendung als heilmittel
TW313568B (pt) 1994-12-20 1997-08-21 Hoffmann La Roche
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
RU2172735C2 (ru) 1995-12-20 2001-08-27 Яманоути Фармасьютикал Ко., Лтд. Арилэтенсульфонамидные производные и фармацевтическая композиция
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
TWI284642B (en) 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
US6596719B1 (en) 1999-09-03 2003-07-22 Actelio Pharmaceuticals Ltd. 6 alkoxy-4-pyrimidinyl bis-sulfonamides
WO2001046156A1 (en) 1999-12-22 2001-06-28 Actelion Pharmaceuticals Ltd. Butyne diol derivatives
US20040062803A1 (en) 1999-12-22 2004-04-01 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor
ES2236028T3 (es) 1999-12-31 2005-07-16 Encysive Pharmaceuticals, Inc Sulfonamidas y sus derivados que modulan la actividad de la endotelina.
WO2001081335A1 (en) 2000-04-20 2001-11-01 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
WO2001081338A1 (en) 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
JP2001335469A (ja) 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
AU2001271639A1 (en) 2000-06-28 2002-01-08 Teva Pharmaceutical Industries Ltd. Carvedilol
CN1486302A (zh) 2000-12-07 2004-03-31 CV���ƹ�˾ 作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶
CN100432070C (zh) * 2000-12-18 2008-11-12 埃科特莱茵药品有限公司 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
FR2819720B1 (fr) 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
KR20030041577A (ko) 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
AU2003208444B2 (en) 2002-02-26 2006-10-26 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
AU2003285321B2 (en) * 2002-12-02 2010-04-08 Actelion Pharmaceuticals Ltd Pyrimidine-sulfamides and their use as endothelian receptor antagonist
WO2004075894A1 (en) 2003-02-25 2004-09-10 Eli Lilly And Company Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
CA2621273C (en) 2005-09-12 2014-07-29 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
DK2254570T3 (da) 2008-02-20 2014-02-03 Actelion Pharmaceuticals Ltd Kombination omfattende paclitaxel til behandling af ovariecancer
JP5764061B2 (ja) 2008-08-13 2015-08-12 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ マシテンタン含有治療用組成物

Also Published As

Publication number Publication date
DK2190837T3 (da) 2012-10-08
KR20100052517A (ko) 2010-05-19
CA2695511C (en) 2015-11-03
CN101772494A (zh) 2010-07-07
PT2190837E (pt) 2012-10-31
AU2008290234A1 (en) 2009-02-26
TW200927122A (en) 2009-07-01
AR070018A1 (es) 2010-03-10
NZ583990A (en) 2012-06-29
BRPI0815360B1 (pt) 2018-12-04
AU2008290234B2 (en) 2013-11-21
WO2009024906A1 (en) 2009-02-26
RU2485116C2 (ru) 2013-06-20
MA31702B1 (fr) 2010-09-01
BRPI0815360A8 (pt) 2017-12-26
JP2010536742A (ja) 2010-12-02
CN101772494B (zh) 2013-05-15
US8324232B2 (en) 2012-12-04
SI2190837T1 (sl) 2012-11-30
MX2010001837A (es) 2010-03-10
EP2190837A1 (en) 2010-06-02
US20120142716A1 (en) 2012-06-07
TWI411437B (zh) 2013-10-11
IL203936A (en) 2016-03-31
ES2394584T3 (es) 2013-02-04
EP2190837B1 (en) 2012-08-15
MY152281A (en) 2014-09-15
ZA201001872B (en) 2011-05-25
CA2695511A1 (en) 2009-02-26
HRP20120878T1 (hr) 2012-11-30
PL2190837T3 (pl) 2013-01-31
BRPI0815360A2 (pt) 2015-02-10
KR101528946B1 (ko) 2015-06-15
RU2010109543A (ru) 2011-09-27
CY1113255T1 (el) 2016-04-13
JP5323075B2 (ja) 2013-10-23
HK1144196A1 (en) 2011-02-02

Similar Documents

Publication Publication Date Title
BRPI0815360B8 (pt) composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto
CR20110233A (es) Nuevos compuestos halosustituidos
UY32296A (es) Nuevos compuestos
ECSP12012334A (es) Morfolinopirimidinas y su uso en terapia
GEP20227397B (en) Inhibitors of influenza viruses replication
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
UY31611A1 (es) Compuestos que comprenden un grupo ciclobutoxi
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
BRPI0906475A2 (pt) Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto
BR112012005962A8 (pt) Conjugados de proteína quinase, compostos e composição farmacêutica compreendendo os referidos compostos
CR11623A (es) Compuestos
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
DOP2010000387A (es) Compuestos pirazolicos 436
BRPI1016219B8 (pt) composto indazol substituído com oxazol, e, composição farmacêutica
DOP2010000357A (es) Derivados de indazoles sustituidos con fenilo o piridinilo
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
BR112015012720A2 (pt) derivados de feniletilpiridina como inibidores de pde4
BRPI0916069B8 (pt) composto, usos de um composto e composição farmacêutica
CL2008002726A1 (es) Compuestos derivados de isoquinolinilo e isoindolinilo, antagonistas de histamina-3; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos del sistema nervioso c
BR112013008211A8 (pt) Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende
BR112013004662B8 (pt) Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
BRPI1014802B8 (pt) profármacos de triptolida.
BR112015014822A2 (pt) compostos de fórmula i, composição, utilização de um composto, método para o combate dos fungos nocivos e semente revestida
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/12/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF